Advertisement

Topics

"Biotech Verlust Millionen Franken Halbjahr" Drugs and Medication Database

21:25 EST 12th December 2018 | BioPortfolio

Here are the most relevant "Biotech Verlust Millionen Franken Halbjahr" Drugs and Medications that we have found in our database.

More Information about "Biotech Verlust Millionen Franken Halbjahr" on BioPortfolio

We have published hundreds of Biotech Verlust Millionen Franken Halbjahr news stories on BioPortfolio along with dozens of Biotech Verlust Millionen Franken Halbjahr Clinical Trials and PubMed Articles about Biotech Verlust Millionen Franken Halbjahr for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biotech Verlust Millionen Franken Halbjahr Companies in our database. You can also find out about relevant Biotech Verlust Millionen Franken Halbjahr Drugs and Medications on this site too.

Showing "Biotech Verlust Millionen Franken Halbjahr" Drugs and Medications, all 10

Probably Relevant

Ocufresh [Taiwan Biotech Co, Ltd]

Minidrops [Taiwan Biotech Co, Ltd]

Iman time control all day moisture complex spf 15 [Sheencolor Biotech Co., Ltd.]

Drug Fact

Iman time control oil free moisture complex spf 15 [Sheencolor Biotech Co., Ltd.]

Drug Fact

Possibly Relevant

Stelara [Janssen Biotech, Inc.]

These highlights do not include all the information needed to use STELARA safely and effectively. See full prescribing information for STELARA. STELARA (ustekinumab) Injection, for subcutaneous useInitial U.S. Approval: 2009

Collagenase santyl [HEALTHPOINT, LTD]

Collagenase Santyl Ointment 250 units/g

Hematogen fa [Nnodum Pharmaceuticals]

Hematogen FA

Vivotif-b [Rebel Distributors Corp]

Vivotif-B

Hematogen forte [Nnodum Pharmaceuticals]

Hematogen Forte Soft Gelcap

Simponi [Janssen Biotech, Inc.]

These highlights do not include all the information needed to use SIMPONI (golimumab) safely and effectively. See full prescribing information for SIMPONI. SIMPONI (golimumab) Injection, solution for subcutaneous useInitial U.S. Approval: 2009



Advertisement
Quick Search
Advertisement
Advertisement